Homotherapy for heteropathy of chronic kidney disease and oligoasthenozoospermia through regulating SIRT1/NF-κB pathway by Shenqi pills
SQP demonstrates therapeutic potential for CKD and OA by targeting the SIRT1/NF-κB signaling pathway, providing evidence for its clinical application in treating kidney-yang deficiency-related diseases.
Authors
- Ping Qiu (ORCID: https://orcid.org/0000-0003-4090-5704)
- Sichen Wang (ORCID: https://orcid.org/0009-0002-8492-3234)
- Qihan Luo
- Yiming Liu (ORCID: https://orcid.org/0000-0003-2175-1770)
- Changyu Li (ORCID: https://orcid.org/0000-0001-8656-0428)
- Shuo Huang (ORCID: https://orcid.org/0000-0002-9116-1242)
- Xinyue Li (ORCID: https://orcid.org/0009-0009-4259-6934)
- Jiale Wei (ORCID: https://orcid.org/0009-0008-3274-4668)
Institutions
- Zhejiang Chinese Medical University (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-06-09
- DOI
- https://doi.org/10.3389/fphar.2025.1551423
- Primary Topic
- Complementary and Alternative Medicine Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Zhejiang Chinese Medical University